News | October 16, 2012

SNMMI Issues Updated Guideline for Therapy of Thyroid Disease with I-131

October 16, 2012 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued an updated practice guideline on the treatment of thyroid cancer patients with I-131 (sodium iodide). Published in the October issue of the Journal of Nuclear Medicine (JNM), the guideline serves as an educational tool designed to assist trained practitioners in evaluating patients for therapy with I-131 for benign or malignant diseases of the thyroid gland, performing this treatment in a safe and appropriate manner, understanding and evaluating the pathological conditions resulting from the therapy, and reporting the outcomes of therapy.

“A great deal was changed in this new version of the guideline for I-131 therapy,” said Edward B. Silberstein, M.D., lead author of the guideline. “We have defined the levels of risk of thyroid cancer to patients which help determine the treatment needed, addressed the adverse effects of therapy, detailed the guidelines and regulations for patient release after I-131 therapy, and much more.”

Oral administration of I-131 has been a commonly accepted procedure for treatment of benign and malignant disorders of the thyroid since the 1940s. Physicians responsible for treating thyroid cancer patients should have an understanding of the clinical pathophysiology and natural history of the disease processes, be familiar with alternative forms of therapy, and be able to collaborate closely with other physicians involved in the management of the patient’s condition. The treating physician should either see patients in consultation with the physician assuming overall management of the patient’s condition or be prepared to assume that role. In the United States, the treating physician should be board-certified in nuclear medicine or able to document equivalent training, competency and experience in the safe use and administration of therapeutic I-131.

Licensure to possess I-131 and regulations regarding the release of patients treated with radioiodine, while governed by the Nuclear Regulatory Commission, vary from jurisdiction to jurisdiction. Physicians engaged in therapy with I-131 must be knowledgeable about, and in compliance with, all applicable laws and regulations. The facility in which treatment is performed must have appropriate personnel, radiation safety equipment and procedures available for waste handling and disposal, monitoring personnel for accidental contamination and controlling spread of I-131 to conform to state and federal regulations. All physicians engaged in therapy have a duty to ensure that their knowledge and competencies are up to date.

The SNMMI practice guideline for I-131 therapy for thyroid cancer reviews common clinical indications; qualifications and responsibilities of personnel; procedures and specifications of the examination; documentation and reporting; equipment specifications, quality control and improvement, safety, infection control and patient education concerns; and radiation dosimetry.

“In addition, we’ve also highlighted 14 issues that require further clarification, such as the diagnostic role of alternative imaging agents for thyroid cancer, the frequency and length of long-term follow-up after I-131 therapy, and others. SNMMI will work to address these issues in future versions of the guideline,” noted Silberstein.

Each practice guideline, representing a policy statement by SNMMI, undergoes a thorough consensus process in which it has been subjected to extensive review, requiring the approval of the Committee on Guidelines and SNMMI Board of Directors. SNMMI emphasizes that the safe and effective use of diagnostic nuclear medicine imaging requires specific training, skills, and techniques, as described in each document.

For more information: www.snmmi.org/guidelines

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
Overlay Init